You have no items in your shopping cart.
CD25 Antibody
Description
Research Area
Images & Validation
−| Tested Applications | FC, IF, WB |
|---|---|
| Dilution range | WB (1/500 - 1/1000), IF/IC (1/50 - 1/200), FC (1/500 - 1/2000) |
| Reactivity | Human |
| Application Notes |
Key Properties
−| Antibody Type | Primary Antibody |
|---|---|
| Host | Mouse |
| Clonality | Monoclonal |
| Clone No. | JM7B6 |
| Immunogen | Native purified human CD25. |
| Purification | The antibody was purified by affinity chromatography. |
| Conjugation | Unconjugated |
Storage & Handling
−| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
|---|---|
| Form/Appearance | Mouse IgG2a. Liquid in PBS, pH 7.3, and 0.02% sodium azide. |
| Disclaimer | For research use only |
Alternative Names
−Similar Products
−Anti-IL-2R alpha (CD25) [Basiliximab] [orb1152522]
Blocking, FC, IF, IHC, WB
Human, Primate
Human
Monoclonal
Unconjugated
0.2 mgAnti-IL-2R alpha (CD25) [Basiliximab] [orb348865]
Blocking, FC, IF, IHC, WB
Human, Primate
Human
Monoclonal
Unconjugated
0.2 mgAnti-IL-2R alpha (CD25) [Basiliximab] [orb348908]
Blocking, FC, IF, IHC, WB
Human, Primate
Human
Monoclonal
Unconjugated
0.2 mg

Quality Guarantee
Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Flow cytometric analysis of human lymphocytes treated with PHA using Anti-CD25 Antibody, followed by anti-mouse IgG PE.
Documents Download
Request a Document
Protocol Information
CD25 Antibody (orb248904)
Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.
Login to Submit a Review






![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb1152522_1.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb1152522_2.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb1152522_3.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb1152522_4.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb1152522_5.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb1152522_6.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348865_1.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348865_2.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348865_3.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348865_4.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348865_5.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348865_6.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348908_1.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348908_2.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348908_3.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348908_4.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348908_5.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348908_6.png)





